Skip to content

Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG

Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04934865
Acronym
REAL-MOOV-LUNG
Enrollment
240
Registered
2021-06-22
Start date
2021-10-07
Completion date
2025-02-28
Last updated
2025-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

Evaluation of patient's proportion, whose management care has been modified at least once and specially by Moovcare® Lung application at 12 and 24 months.

Detailed description

Primary objective of the study: The primary objective is a clinical one and is to evaluate the proportion of patients, whose management care has been modified at least once and specially by Moovcare® Lung application at 12 and 24 months.

Interventions

DEVICEPatients treated for their lung cancer.

In addition to the weekly Moovcare® Lung follow-up, patients will benefit from standard oncological follow-up at the discretion of their oncologist according to standard recommendations for 2 years. Questionnaires will be completed at different times as mentioned below on the global study scheme and Flowchart. In an active treatment situation, the pace of consultations will be adapted to the pace of treatment administration, according to standard recommendations. It may be lengthened in the absence of a clinical application or biological alert at the discretion of the investigator.

Sponsors

Institut Curie
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient with lung cancer at any diagnostic stage and histology. 2. Patient willing to use the follow-up setting with Moovcare® Lung apps. 3. Age ≥ 18 years. 4. Patient received anti-cancer treatment (surgery, chemotherapy, radiation (stereotaxy or not) or radio-chemotherapy association ended less than 12 weeks (Cohort 1 post-treatment); or during maintenance treatment or consolidation by chemotherapy or targeted therapy, or by immunotherapy initiated less than 12 weeks (Cohort 2 during treatment). 5. Imaging tumor evaluation less than 12 weeks showing disease control (response or stability according to RECIST 1.1 criteria). 6. Patient with symptomatic score on Moovcare® Lung apps less than 7. 7. Patient (or relatives) with internet access, a personnal e-mail box and a smartphone. 8. Patient with social security affiliation. 9. Signed informed consent form.

Exclusion criteria

1. Patient with progression after the first evaluation of initial treatment. 2. Pregnancy and breast-feeding. 3. Patient under tutorship or guardianship. 4. Dementia, mental alteration or psychiatric pathology influencing patient consent procedure and/or protocol observance and study follow-up. 5. Patient enable to protocol follow-up for psychological, social, familial or geographical reasons.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients.24 monthsProportion of patients whose care management was modified at least once and specifically by Moovcare® Lung application at months.

Secondary

MeasureTime frameDescription
Clinical aspects : Number of unscheduled hospitalizations.24 monthsNumber of unscheduled hospitalizations.
Clinical aspects : Duration of unscheduled hospitalizations.24 monthsDuration of unscheduled hospitalizations.
Clinical aspects : Number of overall hospitalizations.24 monthsNumber of overall hospitalizations.
Clinical aspects : Duration of overall hospitalizations.24 monthsNumber of overall hospitalizations.
Clinical aspects : Quality of life.Every 3 months until 24 monthsQuality of life criteria with EORTC QLQ-C30 questionnaire scale.
Clinical aspects : Overall survival over the entire follow-up.24 monthsOverall survival over the entire follow-up.
Clinical aspects : date of consultation.24 monthsInterval between the date of early consultation or early scan and the date of the scheduled consultation or scan.
Organizational aspects : Time for each investigating center24 monthsCalculation of the time spent to set up the protocol and the application for each investigating center.
Organizational aspects : Functioning and processing of alerts :24 monthsTime spent to register patients.
Organizational aspects : Patient satisfaction.3, 6, 12, 18 and 24 months of use of the applicationThe degree of patient satisfaction will be evaluated with a satisfaction questionnaire. A form to be filled in after 3, 6, 12, 18 and 24 months of use of the application.
Organizational aspects : Satisfaction of the care teams at 6 months follow-up.6 months follow-upPhysician satisfaction: the satisfaction of all doctors involved will be evaluated with a questionnaire to be filled in (Questionnaire Satisfaction Médecins). Staff satisfaction: the satisfaction of all staff involved (coordinating nurses, secretaries or other categories of staff) will be assessed with a questionnaire to be filled in (Questionnaire Satisfaction Collaborateur).
Organizational aspects : Patient compliance.24 monthsThe compliance will be evaluated by the ratio between the number of completed questionnaires and the invitation's number sent to complete them. Reasons of impossible connection (must be documented on medical records) will be subtracted from the calculation. The number of patients who voluntary abandoned the use of Moovcare® Lung medical device will be reduced considered as non-compliant.
Organizational aspects : all secondary outcome measures12 months of follow-upabove criteria will be assessed at 12 months of follow-up. This analysis will be done one year after inclusion of the last patient.
Organizational aspects : number of stakeholders24 monthsNumber of stakeholders on the application, number of stakeholders specifically recruited for the application and type of stakeholders.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 29, 2026